Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
- Tuesday, December 20, 2022, 7:04
- Finance
- Add a comment
– This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting – – FDA granted the applications Priority Review with a PDUFA date of April 21, 2023 – TOKYO, BOTHELL, Wash. and RAHWAY, N.J., Dec….
About the Author
adminasapcorp has written 41546 stories on this site.